Daily bars for up to one year, weekly bars for the 5-year view. Averages are 50/200 trading days (10/40 weeks on the 5-year view).
Novartis AG (NVS) is trading at $143.33, up 0.44% on the day. Its market value of $272.44B makes it the 50th largest of the 300 companies we follow.
The 52-week range is $118.00 to $165.46. Today's price is about 53% of the way from the low to the high. Holders are ahead 20.1% over twelve months, but down 6.4% across the last three months.
On the chart it has slipped under both the 50-day ($151.80) and 200-day ($148.93) moving averages; RSI is 43, and the last 30 sessions moved at roughly 52% annualized volatility.
In the quarter ended Jun 2026 the company brought in $14.95B of revenue, up 0.8% from a year earlier, with $3.26B of net profit (a 22.5% margin).
Buyers are paying 21.7 times trailing earnings, 21% above its five-year average of 17.9. The median for its industry group is 20.4.
3 analysts follow the stock and the average call is "buy". The mean target, $177.84, sits 24.1% over where the stock trades.
This summary is put together from the numbers on the page and updates when they do. It describes the data; it is not a forecast or a recommendation.
Novartis is a Swiss drugmaker focused on innovative medicines after spinning off Sandoz, with heart, immunology, cancer and neuroscience franchises.
What tends to move it. Sales of Entresto, which is losing patent protection, against newer drugs like Kisqali and Pluvicto, are the central question.
Written by hand by the BeStock desk and revised when a business changes. See how we work. Spot something out of date? Tell us.
Price return over each window, from adjusted daily and weekly closes
| Indicator | Value | Signal |
|---|---|---|
| Price vs 20-day average | -2.4% | Bearish |
| Price vs 50-day average | -5.6% | Bearish |
| Price vs 200-day average | -3.8% | Bearish |
| 50-day vs 200-day | 50d above 200d | Bullish |
| RSI (14) | 43.5 | Bearish |
| MACD (12,26,9) | -3.82 | Bearish |
| Bollinger band position | 41% | Bearish |
Standard indicator readings worked out from daily closes. They describe how the price has behaved, not where it is going.
Quote as of Sep 24, 2026 2:00 pm ET. Prices can lag the live tape. This is background information, not a recommendation.
Ranks are among the 300 or so U.S.-listed stocks BeStock covers, recalculated whenever prices refresh. A row is left out when the measure does not apply, such as yield for a stock that pays no dividend.
Latest reported quarter: Q2, ended Jun 2026
"Implied move" is the size of move the options market was pricing ahead of the report. Move is the stock’s change on the first session after the release.
Multiples measured against the stock's own five-year history
Above its usual level · 70th percentile, 5-year average 17.9x
#1604 of 2977 stocks by PE (1 = cheapest)
Near the top of its 5-year range · 89th percentile, 5-year average 4.7x
#4517 of 5303 stocks by PB (1 = cheapest)
Near the top of its 5-year range · 81st percentile, 5-year average 4.1x
#3760 of 5143 stocks by PS (1 = cheapest)
Dashed line is the 5-year average; the shaded band is one standard deviation either side.
Who holds it, who is betting against it, and where the big money is moving
Net of large-order buying minus selling, in USD. Over this window: −$79.82M (4 inflow days, 16 outflow days).
Across the full calendar years shown, the annual payout grew by roughly 7.0% a year.
$143.33 is the latest print for NVS, a move of +0.44% against yesterday's close of $142.71. Today's low and high so far: $142.91 and $144.65.
Equity value comes to $272.44B at the current price. By that measure it is number 50 of the 300 names in our coverage.
Buyers pay 21.7 times the last twelve months of profit (EPS $7.15). Averaged over five years the multiple has been 17.9, and today's level ranks in the 70th percentile of its own history.
The year's floor is $118.00 and the ceiling $165.46. Shares are 13.4% away from that ceiling.
It does. Payouts over the past twelve months work out to a 3.31% yield; the latest ex-dividend date was March 11, 2026.
Of 3 analysts, 67% say buy, 33% hold and 0% sell. Price targets average $177.84, with the most cautious at $170.00 and the most optimistic at $183.53.
Novartis is a Swiss drugmaker focused on innovative medicines after spinning off Sandoz, with heart, immunology, cancer and neuroscience franchises.
BeStock publishes market data and analysis for information only. Nothing here is investment advice or a solicitation to buy or sell any security. Quotes may be delayed and figures can contain errors; check primary sources before you trade. How we source and calculate these pages.